

Polypipe Group

Sector variation, solid performance

Polypipe is benefiting from its leading position as a supplier into the new housebuilders who are expecting further growth. Other sectors are seeing different conditions but activity levels – including price increases – appear to be holding up reasonably well here also. Our estimates are unchanged and we retain the view that a sector premium rating is warranted.

Year end	Revenue (£m)	PBT* (£m)	EPS* (p)	DPS (p)	P/E (x)	Yield (%)
12/15	352.9	48.0	19.4	7.8	19.6	2.0
12/16	436.9	61.8	25.0	10.1	15.2	2.7
12/17e	465.9	66.2	26.4	11.7	14.4	3.1
12/18e	481.5	71.6	29.0	12.9	13.1	3.4

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles and exceptional items.

Residential leading the way

Overall, group like-for-like (LFL) 10-month revenue growth was +7.1% (including +7.3% in H2 to date), enhanced to 8.2% with FX effects. Against H1, divisional LFL revenue growth in the latest four months (to October) is tracking slightly higher in UK Residential and Commercial & Infrastructure (C&I) Europe and lower in C&I UK Market comments are similar to before with residential newbuild still the standout sector; as Polypipe addresses the full build cycle from below ground through to internal fixes, it offers a good read on activity here. A sluggish road-building programme is continuing to limit volume progress in UK C&I, though price increases have contributed to some revenue growth. This sub-division will also feel some y-o-y drag from reduced business in the Middle East. Polypipe's ventilation products – supplied into both UK divisions – are understood to be growing at least in line with and probably ahead of divisional trends. C&I Europe serves a competitive end customer base and supply chain, but demand conditions are clearly favourable currently.

Minor rebalancing, unchanged headline estimates

Recent housebuilder reports point to stable/robust conditions and an expectation of further progress so this should remain a firm segment. Prospective price increases do influence buyer behaviour; this benefited Q416 and the pattern may recur this year, though order visibility is limited at this stage. We have put through a minor rebalancing of our UK expectations in favour of residential and lowered C&I. This apart, estimates are very much intact. We continue to expect some recovery in EBIT margins next year as input cost increases are recovered and more moderate revenue growth rates than in FY17 (ie +3.3% FY19, +2.8% FY20, both unchanged).

Valuation: Retain sight of sector premium

Having traded largely between 380-420p since April, Polypipe's share price currently sits below this range, having sold off in the last week. Market sentiment has softened a little and construction-related exposure more so. The current year P/E and EV/EBITDA are now 14.4x and 10.0x, respectively. Sector constituent ratings are polarising; Polypipe is on a c 7% sector P/E premium only and still on discounts to mid-250 peers Marshalls and Howden.


Trading update

Construction & materials

22 November 2017

Price	381.1p
Market cap	£756m
	€1.12/£
Net debt (£m) at end June 2017	178.0
Shares in issue	198.4m
Free float	93%
Code	PLP
Primary exchange	LSE
Secondary exchange	N/A

Share price performance



Business description

Polypipe Group is a leading European supplier of plastic building products and ventilation systems. UK operations (c 87% of annualised FY16 net revenue and c 98% of EBIT) address a broad range of sectors including residential, commercial and civil building demand and a number of subsectors within them. Overseas operations are located in France and Italy with a new manufacturing facility in the Middle East.

Next events

FY17 results	20 March 2018

Analyst

Toby Thorrington +44 (0)20 3077 5721

industrials@edisongroup.com

Edison profile page

Polypipe Group is a research client of Edison Investment Research Limited



Exhibit 1: Financial summary

	£m	2014	2015	2016	2017e	2018e	2019e
Year end 31 December		IFRS	IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS							
Revenue		327.0	352.9	436.9	465.9	481.5	495.0
Cost of Sales		(202.4)	(210.0)	(256.8)	(277.0)	(283.6)	(290.1)
Gross Profit		124.6	142.9	180.1	188.9	197.9	204.9
EBITDA		60.8	69.3	86.4	90.8	96.6	100.8
Operating Profit (underlying)		46.3	54.2	70.4	74.5	80.1	84.0
SBP		0.0	0.0	(1.0)	(1.2)	(1.3)	(1.3)
Operating Profit (reported)		46.3	54.2	69.4	73.4	78.8	82.7
Net Interest		(7.7)	(5.3)	(6.6)	(6.0)	(6.0)	(6.0)
Other finance		(1.0)	(0.9)	(1.0)	(1.2)	(1.2)	(1.2)
Intangible Amortisation		0.0	(3.0)	(6.8)	(5.6)	(5.6)	(5.6)
Exceptionals		(20.7)	(3.5)	(0.6)	(1.2)	0.0	0.0
Profit Before Tax (norm)		37.6	48.0	61.8	66.2	71.6	75.5
Profit Before Tax (FRS 3)		16.9	41.5	54.4	59.4	66.0	69.9
Tax		(5.4)	(9.2)	(11.8)	(13.2)	(13.6)	(13.6)
Profit After Tax (norm)		32.2	38.8	50.0	52.9	58.0	61.9
Profit After Tax (FRS 3)		11.5	32.3	42.6	46.1	52.4	56.3
					-		
Average Number of Shares Outstanding (m)		199.9	199.3	198.9	199.3	199.3	199.3
EPS - normalised (p)		16.1	19.4	25.0	26.4	29.0	30.9
EPS - FRS 3 (p)		5.8	16.2	21.4	23.1	26.3	28.3
Dividend per share (p)		4.5	7.8	10.1	11.7	12.9	14.2
Gross Margin (%)		38.1	40.5	41.2	40.6	41.1	41.4
EBITDA Margin (%)		18.6	19.6	19.8	19.5	20.1	20.4
Operating Margin (underlying) (%)		14.2	15.4	16.1	16.0	16.6	17.0
BALANCE SHEET							
Fixed Assets		324.2	476.5	472.6	475.8	473.7	471.3
Intangible Assets		235.0	378.4	371.6	366.0	360.4	354.8
Tangible Assets		89.2	98.1	101.0	109.8	113.3	116.5
Investments		0.0	0.0	0.0	0.0	0.0	0.0
Current Assets		103.9	99.6	119.5	162.5	194.3	228.2
Stocks		39.9	47.5	52.2	56.3	57.6	59.0
Debtors		20.2	29.3	38.9	40.6	42.4	43.7
Cash		43.1	21.6	26.5	63.7	91.9	122.7
Current Liabilities		(69.8)	(87.2)	(104.5)	(107.6)	(108.5)	(109.0)
Creditors		(69.8)	(87.2)	(104.5)	(107.6)	(108.5)	(109.0)
Short term borrowings		0.0	0.0	0.0	0.0	0.0	0.0
Long Term Liabilities		(120.6)	(227.9)	(200.2)	(216.6)	(217.7)	(218.7)
Long term borrowings		(118.0)	(215.9)	(190.8)	(207.0)	(207.0)	(207.0)
Other long term liabilities		(2.6)	(12.0)	(9.4)	(9.6)	(10.7)	(11.7)
Net Assets		237.7	261.0	287.4	314.0	341.8	371.8
CASH FLOW							
Operating Cash Flow		50.6	72.6	86.5	87.6	93.2	97.7
Net Interest		(10.4)	(5.7)	(7.3)	(6.0)	(6.0)	(6.0)
Tax		(3.7)	(5.2)	(10.1)	(12.5)	(13.2)	(13.6)
Capex		(14.9)	(18.9)	(18.7)	(24.8)	(20.0)	(20.0)
Acquisitions/disposals		(0.3)	(149.5)	0.0	0.0	0.0	0.0
Financing		(1.7)	0.0	(2.9)	(1.5)	(1.5)	(1.5)
Dividends		(3.0)	(10.6)	(17.1)	(21.1)	(24.2)	(25.8)
Net Cash Flow		16.6	(117.3)	30.5	21.7	28.3	30.8
Opening net debt/(cash)		84.7	74.9	194.3	164.3	143.3	115.1
HP finance leases initiated		(9.6)	(1.7)	0.0	0.0	0.0	0.0
Other		2.8	(0.4)	(0.5)	(0.7)	0.0	0.0
Closing net debt/(cash)		74.9	194.3	164.3	143.3	115.1	84.3

Source: Polypipe Group accounts, Edison Investment Research



Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the <u>Financial Conduct Authority</u>. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison Is registered on the New Zealand Financial Services Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085669] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Research Limited [4794244]. <u>www.edisongroup.com</u>

DISCLAIMER

Disclanding and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison for investment Research and is used by Edison for publication globally. All information used in the publication of this report has been compiled from public available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publicating described in the lumestment Research may not be eligible for sate in all jurisdictions or to certain categories of investment. This describes and the inderse of the comportations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers" exclusions" from the definition of investment adviser under Section 202(a)(11) of the Investment Adviser and the Sectific and the information tabut contrastic advises and the information tabut companies in which we believe our readers may be interested and this information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended to find from All of the purpose of the purpose of the purpose of the formation purposes only and should not be construed and divers. All colicitation or inducement to buy, sell, subscribe, or underwite any securities mentioned or in the topic of this document. This document is provided for information approaces on y and should not be construed as an origination of investment these and and users or torokers information approaces for any or related securities mentioned or in the projot of the formation approaces on solicitation ore inducement to buy, sell, subscribe, or underwite an

Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom New York +1 646 653 7026 295 Madison Avenue, 18th Floor 10017, New York US Sydney +61 (0)2 8249 8342 Level 12, Office 1205 95 Pitt Street, Sydney NSW 2000, Australia